Insight

The future of oncology:

A focused approach to winning in 2030

Oncology treatments used to promise some of the highest returns for pharmaceutical manufacturers. But spiralling R&D costs, shorter product lifecycles, fragmented patient markets and pressure on healthcare budgets are changing the industry’s status quo, threatening revenues and opening the door to new entrants.

Value-based pricing is on the rise, as cash-strapped healthcare providers attempt to cut costs. At the same time, technological advances are uncovering smaller oncology patient subsets based upon genomic and other forms of profiling. 

 

The future of oncology:

A focused approach to winning in 2030

Related content

Our practice

KPMG can help healthcare and life sciences organizations solve their toughest business challenges.